PRIAS: Active surveillance for men with low risk prostate cancer
Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The Nethe...
24 Feb 2020
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic...
Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
19 Feb 2020
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Dr Julie Graff - Oregon Health & Science University, Portland, USA
19 Feb 2020
BCG dosing for bladder cancer: Standard frequency schedule correct
Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany
19 Feb 2020
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA
19 Feb 2020
Integrative molecular characterisation of S/R RCC to reveal determinants of poor...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
18 Feb 2020
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or ...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
18 Feb 2020
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advan...
Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom
18 Feb 2020
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients
Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec
18 Feb 2020
ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and no...
Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob
14 Feb 2020
Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer
Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, ...
14 Feb 2020
